ATE184473T1 - USE OF GLYCERINE TO ATTENUATE TRANSDERMAL DRUG ADMINISTRATION - Google Patents

USE OF GLYCERINE TO ATTENUATE TRANSDERMAL DRUG ADMINISTRATION

Info

Publication number
ATE184473T1
ATE184473T1 AT93913793T AT93913793T ATE184473T1 AT E184473 T1 ATE184473 T1 AT E184473T1 AT 93913793 T AT93913793 T AT 93913793T AT 93913793 T AT93913793 T AT 93913793T AT E184473 T1 ATE184473 T1 AT E184473T1
Authority
AT
Austria
Prior art keywords
drug
application
transdermal
delivery
glycerin
Prior art date
Application number
AT93913793T
Other languages
German (de)
Inventor
Werner E Heiber
Charles D Ebert
Dinesh C Patel
Srinivasan Venkateshwaran
Original Assignee
Theratech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratech Inc filed Critical Theratech Inc
Application granted granted Critical
Publication of ATE184473T1 publication Critical patent/ATE184473T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body

Abstract

A transdermal/transmucosal drug delivery system utilizes glycerin to moderate the initial burst effect of transdermal drug delivery and also maintain the delivery to the derma/mucosa at a relatively sustained rate over the duration of the application to either an application or afflicted situs. The drug composition contains an effective amount of a percutaneously absorbable drug and an amount of glycerin which is effective to moderate and maintain the transdermal delivery of the drug. The system also contains means for maintaining the drug composition in a drug transferring relationship with the derma/mucosa. When applied to an afflicted situs the composition is preferably a gel, cream, lotion or ointment. When applied to an application situs the compositions are contained within a device such as a matrix or liquid reservoir patch which is held to the application site by means of the adhesive. The drug composition may contain glycerin in amounts of between about 0.1 to 50 % by volume.
AT93913793T 1992-06-11 1993-05-03 USE OF GLYCERINE TO ATTENUATE TRANSDERMAL DRUG ADMINISTRATION ATE184473T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89726992A 1992-06-11 1992-06-11

Publications (1)

Publication Number Publication Date
ATE184473T1 true ATE184473T1 (en) 1999-10-15

Family

ID=25407656

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93913793T ATE184473T1 (en) 1992-06-11 1993-05-03 USE OF GLYCERINE TO ATTENUATE TRANSDERMAL DRUG ADMINISTRATION

Country Status (13)

Country Link
EP (1) EP0644746B1 (en)
JP (1) JPH08501529A (en)
KR (1) KR950701508A (en)
AT (1) ATE184473T1 (en)
AU (1) AU677206B2 (en)
CA (1) CA2135925C (en)
DE (1) DE69326461T2 (en)
DK (1) DK0644746T3 (en)
ES (1) ES2137993T3 (en)
GR (1) GR3031246T3 (en)
HU (1) HU221598B (en)
NZ (1) NZ253409A (en)
WO (1) WO1993025168A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4429667C2 (en) * 1994-08-20 1996-07-11 Lohmann Therapie Syst Lts Estradiol TTS with water-binding additives and process for its preparation
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
DE19517145C2 (en) * 1995-05-10 2000-02-24 Hexal Pharmaforschung Gmbh Transdermal therapeutic system (TTS) for administration of testosterone
US6572879B1 (en) * 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
EP0747092B1 (en) * 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
EP0813887A3 (en) * 1996-06-20 1999-11-03 Hisamitsu Pharmaceutical Co. Inc. A device structure for iontophoresis
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
IT1294748B1 (en) 1997-09-17 1999-04-12 Permatec Tech Ag FORMULATION FOR A TRANSDERMAL DEVICE
IL136042A (en) 1997-11-10 2005-12-18 Cellegy Pharma Inc Alcohol-containing composition for topical application
DE10019311A1 (en) * 2000-04-19 2001-10-31 Lohmann Therapie Syst Lts Transdermal therapeutic system used for treating hypertension has reservoir layer based on hydrophilic polymer and/or containing saturated and unsaturated fatty acids
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ATE460939T1 (en) * 2000-08-30 2010-04-15 Unimed Pharmaceuticals Llc METHOD FOR TREATING ERECTIVE DISORDER AND INCREASE LIBIDO IN MEN
WO2004000263A1 (en) 2002-06-25 2003-12-31 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
MXPA05004278A (en) 2002-10-25 2005-10-05 Foamix Ltd Cosmetic and pharmaceutical foam.
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
JO2492B1 (en) * 2003-04-28 2009-10-05 شيرينج ايه جي pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
US7879357B2 (en) * 2003-04-28 2011-02-01 Bayer Schering Pharma Ag Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
KR20130114229A (en) 2005-06-03 2013-10-16 애크럭스 디디에스 피티와이 리미티드 Method and composition for transdermal drug delivery
US8147815B2 (en) * 2005-12-16 2012-04-03 Celmatrix Corporation Topical administration carrier composition and therapeutic formulations comprising same
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
EP2106272A4 (en) 2007-01-11 2011-05-04 Acrux Dds Pty Ltd Spreading implement
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
FR2924942B1 (en) * 2007-12-14 2012-06-15 Pf Medicament TRANSCUTANEOUS PHARMACEUTICAL COMPOSITIONS CONTAINING STEROIDAL HORMONE
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
NZ597237A (en) * 2009-06-12 2014-02-28 Adagio Pharmaceuticals Ltd Sublingual apomorphine
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CA2776474C (en) 2009-10-02 2021-01-12 Foamix Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
DK2651357T3 (en) 2010-12-16 2020-06-02 Sunovion Pharmaceuticals Inc Sublingual film
JP5876468B2 (en) * 2011-02-25 2016-03-02 久光製薬株式会社 Adjuvant for transdermal or transmucosal administration and pharmaceutical preparation containing the same
ES2744454T3 (en) 2013-10-31 2020-02-25 Hisamitsu Pharmaceutical Co Adjuvant composition
USD750788S1 (en) 2013-11-26 2016-03-01 Acrux Dds Pty Ltd Topical spreading applicator
USD749225S1 (en) 2013-11-26 2016-02-09 Acrux Dds Pty Ltd Topical spreading applicator
US8785426B1 (en) * 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
CA3019769C (en) 2015-04-21 2021-10-12 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
MX2020012139A (en) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Compositions and methods for treating rosacea and acne.
US9962444B2 (en) 2016-09-27 2018-05-08 Shane Malek Pharmacokinetically extended action topical hair growth formulation, and administration method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2920500A1 (en) * 1979-05-21 1980-11-27 Boehringer Sohn Ingelheim PHARMACEUTICAL PREPARATION IN THE FORM OF A POLYACRYLATE FILM
JPS6272611A (en) * 1985-09-27 1987-04-03 Kao Corp Skin external preparation
US5059189A (en) * 1987-09-08 1991-10-22 E. R. Squibb & Sons, Inc. Method of preparing adhesive dressings containing a pharmaceutically active ingredient
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
GB9016056D0 (en) * 1990-07-21 1990-09-05 Chatfield Pharmaceuticals Limi Transdermal medicine delivery devices
DE4210165A1 (en) * 1991-07-30 1993-02-04 Schering Ag TRANSDERMAL THERAPEUTIC SYSTEMS
US5405366A (en) * 1991-11-12 1995-04-11 Nepera, Inc. Adhesive hydrogels having extended use lives and process for the preparation of same

Also Published As

Publication number Publication date
NZ253409A (en) 1996-09-25
CA2135925C (en) 2001-04-10
HU221598B (en) 2002-11-28
GR3031246T3 (en) 1999-12-31
KR950701508A (en) 1995-04-28
DE69326461T2 (en) 2000-05-04
JPH08501529A (en) 1996-02-20
CA2135925A1 (en) 1993-12-23
EP0644746A4 (en) 1995-09-13
EP0644746B1 (en) 1999-09-15
DE69326461D1 (en) 1999-10-21
AU4369493A (en) 1994-01-04
WO1993025168A1 (en) 1993-12-23
DK0644746T3 (en) 1999-12-20
EP0644746A1 (en) 1995-03-29
HU9403555D0 (en) 1995-02-28
ES2137993T3 (en) 2000-01-01
AU677206B2 (en) 1997-04-17
HUT71521A (en) 1995-12-28

Similar Documents

Publication Publication Date Title
ATE184473T1 (en) USE OF GLYCERINE TO ATTENUATE TRANSDERMAL DRUG ADMINISTRATION
US5614211A (en) Oxybutynin transdermal device having decreased delamination
KR101050672B1 (en) Therapeutic bandages with polysiloxane substrates containing capsaicin
PT922453E (en) PREPARATION OF THE TYPE OF PERCUTANEOUS ABSORPTION CONTAINING TULOBUTEROL
BR9713492A (en) glycolic acid fatty acid esters and their salts as permeation enhancers
DE122012000021I1 (en) Skin penetration requester as well as those using it.
DK567088D0 (en) DEVICE FOR TRANSDERMAL MEDICINE ADMINISTRATION
NZ306249A (en) matrix patch containing triacetin as a transdermal pentration enhancer
DE3277453D1 (en) Use of eucalyptol for enhancing skin permeation of bioaffecting agents
DE69401945T2 (en) INTRODUCTION OF A POLY-N-VINYLAMID INTO A TRANSDERMAL SYSTEM
DK626484D0 (en) ACTIVE SUBSTANCE DELIVERY SYSTEMS
EP0251464A3 (en) Composition for the control of insects
LU86929A1 (en) NEW TOPICALLY APPLICABLE PHARMACEUTICAL COMPOSITIONS WITH SYSTEMIC EFFECT
KR850700218A (en) Pharmaceutical composition
NZ332746A (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease
GB2163956A (en) Percutaneous anaesthetic composition for topical application
JPH03505835A (en) Transdermal drug delivery system
KR970705381A (en) An estradiol transdermal therapeutic system containing an absorbable additive
US4834980A (en) Transdermal delivery of azatidine
RU94010496A (en) Nootropic agent and medicinal composition of nootropic agent
Hollingsbee et al. The effect of a hydrocolloid dermatological patch (Actiderm) in potentiating the skin blanching activity of triamcinolone acetonide
TH35053A (en) Local anesthetic for external use.